Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence.

Cell-mediated drug-delivery systems have received considerable attention for their enhanced therapeutic specificity and efficacy in cancer treatment. Neutrophils (NEs), the most abundant type of immune cells, are known to penetrate inflamed brain tumours. Here we show that NEs carrying liposomes that contain paclitaxel (PTX) can penetrate the brain and suppress the recurrence of glioma in mice whose tumour has been resected surgically. Inflammatory factors released after tumour resection guide the movement of the NEs into the inflamed brain. The highly concentrated inflammatory signals in the brain trigger the release of liposomal PTX from the NEs, which allows delivery of PTX into the remaining invading tumour cells. We show that this NE-mediated delivery of drugs efficiently slows the recurrent growth of tumours, with significantly improved survival rates, but does not completely inhibit the regrowth of tumours.

[1]  Shigeru Hosaka,et al.  Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process , 1997, Journal of leukocyte biology.

[2]  A. Mangraviti,et al.  Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[3]  P. Kubes,et al.  Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.

[4]  Zhen Gu,et al.  Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery , 2016 .

[5]  H. Gendelman,et al.  Cell-mediated drug delivery , 2011, Expert opinion on drug delivery.

[6]  N. Hogg,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS Mast cell and macrophage chemokines CXCL 1 / CXCL 2 control the early stage of neutrophil recruitment during tissue in fl ammation , 2013 .

[7]  F. Berenbaum,et al.  Induction of the chemokine IL-8/Kc by the articular cartilage: possible influence on osteoarthritis. , 2012, Joint, bone, spine : revue du rhumatisme.

[8]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[9]  G. Haraldsen,et al.  The murine IL‐8 homologues KC, MIP‐2, and LIX are found in endothelial cytoplasmic granules but not in Weibel‐Palade bodies , 2010, Journal of leukocyte biology.

[10]  J. Lundahl,et al.  Neutrophil activation during transmigration in vivo and in vitro A translational study using the skin chamber model. , 2010, Journal of immunological methods.

[11]  Alberto Mantovani,et al.  Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.

[12]  S. Rankin,et al.  Neutrophil kinetics in health and disease , 2010, Trends in immunology.

[13]  P. Black,et al.  Scale to predict survival after surgery for recurrent glioblastoma multiforme. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[15]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[16]  Rachel C Brown,et al.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells , 2007, Brain Research.

[17]  P A Ward,et al.  Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. , 1984, The Journal of biological chemistry.

[18]  L. Beenen,et al.  A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Broggi,et al.  Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.

[20]  R. Coombes.  New targets for cancer therapy. , 1993, Molecular aspects of medicine.

[21]  R. Boxio,et al.  Mouse Bone Marrow Contains Large Numbers of Functionally Competent Neutrophils , 2022 .

[22]  Q. Ping,et al.  Sequential intra-intercellular nanoparticle delivery system for deep tumor penetration. , 2014, Angewandte Chemie.

[23]  Rose Mary Carroll-Johnson,et al.  The good news and the bad news. , 2002, Nursing diagnosis : ND : the official journal of the North American Nursing Diagnosis Association.

[24]  B. Heit,et al.  PI3K accelerates, but is not required for, neutrophil chemotaxis to fMLP , 2008, Journal of Cell Science.

[25]  Jing Qin,et al.  Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. , 2007, Chemical & pharmaceutical bulletin.

[26]  D. Cockayne,et al.  Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo , 2001, Nature Medicine.

[27]  L. Nabors,et al.  Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. , 2003, Cancer research.

[28]  K. Lu.  Stabilizing nanostructures in metals using grain and twin boundary architectures , 2016 .

[29]  S. Nelander,et al.  Origin of the U 87 MG glioma cell line : Good news and bad news , 2016 .

[30]  T. Springer,et al.  Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. , 1986, Journal of immunology.

[31]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.

[32]  Robert Langer,et al.  Bioresponsive materials , 2016 .

[33]  A. Zychlinsky,et al.  Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.

[34]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[35]  Rickey Miller,et al.  Current Studies of Immunotherapy on Glioblastoma , 2014, Journal of neurology and neurosurgery.

[36]  Erwin G. Van Meir,et al.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.

[37]  G. Ricevuti,et al.  Neutrophil infiltration into human gliomas , 1999, Acta Neuropathologica.

[38]  M. Diamond,et al.  A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen , 1993, The Journal of cell biology.

[39]  J. Raizer,et al.  Chemotherapy in the treatment of malignant gliomas , 2006, Expert review of anticancer therapy.

[40]  R. Prayson,et al.  The pathobiology of glioma tumors. , 2010, Annual review of pathology.

[41]  Mayumi Ono,et al.  Induction of Vascular Endothelial Growth Factor by Tumor Necrosis Factor α in Human Glioma Cells , 1996, The Journal of Biological Chemistry.

[42]  Alyssa D Gregory,et al.  Tumor-associated neutrophils: new targets for cancer therapy. , 2011, Cancer research.

[43]  G. Tomei,et al.  Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  Barclay Morrison,et al.  Permeability of Endothelial and Astrocyte Cocultures: In Vitro Blood–Brain Barrier Models for Drug Delivery Studies , 2010, Annals of Biomedical Engineering.

[45]  S. Nelander,et al.  Origin of the U87MG glioma cell line: Good news and bad news , 2016, Science Translational Medicine.

[46]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[47]  V. Perry,et al.  Recruitment of Neutrophils across the Blood–Brain Barrier: The Role of E- and P-selectins , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  Francis C Szoka,et al.  Barriers to carrier mediated drug and gene delivery to brain tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[49]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[50]  M. Dikshit,et al.  Cytokines Induced Neutrophil Extracellular Traps Formation: Implication for the Inflammatory Disease Condition , 2012, PloS one.

[51]  L. Levy,et al.  Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression , 2013, Cancer Immunology, Immunotherapy.

[52]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[53]  David J. Mooney,et al.  Biomaterials and emerging anticancer therapeutics: engineering the microenvironment , 2015, Nature Reviews Cancer.

[54]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[55]  Eric C. Holland,et al.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.

[56]  D. Hanahan,et al.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.

[57]  A. Easton,et al.  Modulation of blood–brain barrier permeability by neutrophils: in vitro and in vivo studies , 2009, Brain Research.